Lionco Pharmaceutical GroupLtd Past Earnings Performance
Past criteria checks 0/6
Lionco Pharmaceutical GroupLtd's earnings have been declining at an average annual rate of -63.4%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 41.9% per year.
Key information
-63.4%
Earnings growth rate
-63.4%
EPS growth rate
Pharmaceuticals Industry Growth | 10.9% |
Revenue growth rate | -41.9% |
Return on equity | -15.8% |
Net Margin | -72.1% |
Next Earnings Update | 24 Aug 2024 |
Revenue & Expenses Breakdown
How Lionco Pharmaceutical GroupLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 200 | -145 | 215 | 30 |
31 Dec 23 | 197 | -151 | 223 | 29 |
30 Sep 23 | 193 | -237 | 256 | 35 |
30 Jun 23 | 202 | -301 | 328 | 34 |
31 Mar 23 | 237 | -239 | 325 | 33 |
31 Dec 22 | 289 | -196 | 334 | 32 |
30 Sep 22 | 338 | -82 | 305 | 22 |
30 Jun 22 | 463 | 33 | 295 | 21 |
31 Mar 22 | 592 | 51 | 403 | 22 |
31 Dec 21 | 740 | 66 | 514 | 23 |
30 Sep 21 | 885 | 87 | 596 | 26 |
30 Jun 21 | 1,005 | 153 | 694 | 21 |
31 Mar 21 | 1,015 | 129 | 708 | 18 |
31 Dec 20 | 1,001 | 160 | 699 | 20 |
30 Sep 20 | 1,194 | 203 | 848 | 16 |
30 Jun 20 | 1,272 | 168 | 906 | 17 |
31 Mar 20 | 1,530 | 231 | 1,076 | 39 |
31 Dec 19 | 1,635 | 202 | 1,172 | 38 |
30 Sep 19 | 1,699 | 167 | 1,264 | 47 |
30 Jun 19 | 1,690 | 223 | 1,268 | 50 |
31 Mar 19 | 1,709 | 186 | 1,315 | 25 |
31 Dec 18 | 1,669 | 183 | 1,287 | 24 |
30 Sep 18 | 1,610 | 230 | 1,210 | 33 |
30 Jun 18 | 1,488 | 171 | 1,066 | 55 |
31 Mar 18 | 1,209 | 165 | 807 | 51 |
31 Dec 17 | 1,005 | 161 | 614 | 47 |
30 Sep 17 | 734 | 149 | 367 | 26 |
30 Jun 17 | 603 | 140 | 266 | 0 |
31 Mar 17 | 497 | 156 | 177 | 0 |
31 Dec 16 | 479 | 154 | 159 | 0 |
30 Sep 16 | 501 | 151 | 161 | 0 |
30 Jun 16 | 514 | 152 | 166 | 0 |
31 Mar 16 | 551 | 148 | 169 | 0 |
31 Dec 15 | 551 | 150 | 168 | 0 |
30 Sep 15 | 558 | 155 | 158 | 0 |
30 Jun 15 | 556 | 150 | 165 | 0 |
31 Mar 15 | 546 | 142 | 170 | 0 |
31 Dec 14 | 576 | 150 | 181 | 0 |
31 Dec 13 | 494 | 115 | 158 | 0 |
Quality Earnings: 603669 is currently unprofitable.
Growing Profit Margin: 603669 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603669 is unprofitable, and losses have increased over the past 5 years at a rate of 63.4% per year.
Accelerating Growth: Unable to compare 603669's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 603669 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.8%).
Return on Equity
High ROE: 603669 has a negative Return on Equity (-15.83%), as it is currently unprofitable.